Your own cells are the safest cells: autologous MSC therapy minimizes immune risk.
TL;DR
Autologous MSC therapy avoids donor matching, alloimmunization, and donor-disease transmission. Allogeneic products have a documented donor-specific antibody rate on the order of ~11.5%, and immune sensitization matters most when you dose more than once — which is the multi-dose future culture expansion anticipates.
Why this matters if you're considering banking
If you bank your own cells, the product you expand later is still you. That is the safety case for banking, distinct from the efficacy case. Sample-level: we are talking about whose cells go into the vial, not a guaranteed clinical outcome.
Is it safer to use your own stem cells?
On immune risk, yes: no donor matching, no alloimmunization, no donor-disease transmission. Repeat dosing is where allogeneic sensitization matters most.
Donor-specific antibody rate after allogeneic MSC exposure (~11.5% DSA)
TODO — Mark to confirm the source already on the v1 page · TODO · 2014
~11.5% donor-specific antibody rate with allogeneic MSCs. Sensitization is most relevant for repeat dosing. TODO: Mark to lock the full-text citation already used on the v1 page.
Limitation. Figure carried from the v1 page. Full-text citation must be confirmed before publish. DSA rates vary by product, HLA matching, and dosing schedule.
What about efficacy?
The head-to-head trials don't show that donor cells beat your own — they show that young cells beat old ones: the autologous cells in those trials came from older, sicker patients, while the donor cells came from the young and healthy. Banking your cells while they're young closes that gap from both sides: young-cell biology, with none of the immune trade-offs of donor cells.
What evidence counts against this hypothesis?
We searched for trials in which allogeneic MSCs produced no DSA and for autologous safety signals that would undermine the immune-risk claim. Single-dose allogeneic products have been used with acceptable acute safety in several indications; that does not erase sensitization risk on repeat dosing.
What would change our verdict
Replicated evidence that repeat-dose allogeneic MSCs do not induce clinically meaningful alloimmunization in the populations that would use expansion, or a safety signal showing autologous culture-expanded products are not safer on immune endpoints.
Why this confidence grade
The immune-risk reduction is well-supported (no HLA matching, no donor-disease transmission, documented DSA with allogeneic cells). We do not grade this High because of efficacy. Efficacy is mixed-to-parity and is stated separately below — that candor is what makes the safety High believable.
Reviewed by Mark Katakowski, PhD · Last reviewed August 26, 2026